Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3042]
News [6141]
Articles [120]
Editorials [18]
Conferences [181]
elearning [32]
FDA approves imetelstat for low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia
FDA approves imetelstat for low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia
ASCO 2024: Innovative combination therapy shows promise for bladder cancer patients unresponsive to standard treatment
ASCO 2024: Innovative combination therapy shows promise for bladder cancer patients unresponsive to standard...
New glioblastoma treatment reaches human brain tumour and helps immune cells recognise cancer cells
New glioblastoma treatment reaches human brain tumour and helps immune cells recognise cancer cells
Getting personal: Accelerating personalised and precision medicine integration into clinical cancer
Getting personal: Accelerating personalised and precision medicine integration into clinical cancer
Researchers identify key differences in inner workings of immune cells
Researchers identify key differences in inner workings of immune cells
World-first study into precision medicine for high-risk childhood cancer yields extraordinary results
World-first study into precision medicine for high-risk childhood cancer yields extraordinary results
Study finds that a common virus can trigger quicker growth of nasopharyngeal cancer
Study finds that a common virus can trigger quicker growth of nasopharyngeal cancer
ASCO 2024: Promising results from the first clinical trial of an innovative next-generation antibody in patients with advanced solid tumours, especially in melanoma
ASCO 2024: Promising results from the first clinical trial of an innovative next-generation antibody in patients...
ASCO 2024: New ‘Armoured’ CAR produces significant responses in patients whose cancers don't respond to current CAR T cell therapies
ASCO 2024: New ‘Armoured’ CAR produces significant responses in patients whose cancers don't respond to current...
ASCO 2024: Antibody-drug conjugate plus checkpoint inhibitor shows a trend toward improved progression-free survival in PD-L1-positive hormone receptor-positive, HER2-negative breast cancer
ASCO 2024: Antibody-drug conjugate plus checkpoint inhibitor shows a trend toward improved progression-free...

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation